Drug adherence after price changes in a previously compliant population

American Journal of Managed Care

Volumn 19, Issue 3, 2013, Pages

  Hill III, James J ^a   Galusha, Deron ^b   Slade, Martin D ^b   Cullen, Mark R ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

COST BENEFIT ANALYSIS; DRUG COST; HEALTH INSURANCE; HUMAN; LETTER; MEDICATION COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; FEMALE; FINANCIAL MANAGEMENT; MALE; STATISTICS AND NUMERICAL DATA; STATISTICS;

DRUG COSTS; FEMALE; FINANCING, PERSONAL; HUMANS; MALE; MEDICATION ADHERENCE;

EID: 84877755765     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69. (Pubitemid 47026771)
2. Farley JF, Wansink D, Lindquist JH, Parker JC, Maciejewski ML. Medication adherence changes following value-based insurance design. Am J Manag Care. 2012;18(5):265-274.
3. Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365(22):2088-2097.
4. Busch SH, Barry CL, Vegso SJ, Sindelar JL, Cullen MR. Effects of a cost-sharing exemption on use of preventive services at one large employer. Health Aff (Millwood). 2006;25(6):1529-1536. (Pubitemid 44871719)
5. Einav L, Finkelstein A, Ryan S, Schrimpf P, Cullen MR. Selection on moral hazard in health insurance. NBER Working Paper 16969. http://www.nber.org/ papers/w16969. Published April 2011.